Moreover, real‐world studies from the Food and Drug Administration Adverse Event Reporting System also reported significantly increased reports ratios of thyroid cancer (proportional reporting ratio, PRR: 27.43) and papillary thyroid cancer (PRR: 8.68)44, 45 associated with GLP‐1 RAs and DDP4i use. Here, GLP1R is linked to thyroid gland papillary carcinoma.